Search | Clinical Trials Finder

Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia
Interventions: Child(ren) receive an adult-onset result, Child(ren) received a pediatric-onset result, Control - Negative Result, Adolescents who received adult-onset result, Adolescents who received a pediatric-onset result, Adolescent controls - negative for familial variant; Genetic
Lead sponsor: Geisinger Clinic; Other
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Acute Leukemia, Adenomatous Polyposis, Adrenocortical Carcinoma, AML, BAP1 Tumor Predisposition Syndrome, Carney Complex, Choroid Plexus Carcinoma, Constitutional Mismatch Repair Deficiency Syndrome, Diamond-Blackfan Anemia, DICER1 Syndrome, Dyskeratosis Congenita, Emberger Syndrome, Familial Acute Myeloid Leukemia, Familial Adenomatous Polyposis, Fanconi Anemia, Familial Cancer, Familial Wilms Tumor, Familial Neuroblastoma, GIST, Hereditary Breast and Ovarian Cancer, Hereditary Paraganglioma-Pheochromocytoma Syndrome, Hodgkin Lymphoma, Juvenile Polyposis, Li-Fraumeni Syndrome, Lynch Syndrome, MDS, Melanoma Syndrome, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2, Neuroblastoma, Neurofibromatosis Type 1, Neurofibromatosis Type II, Nevoid Basal Cell Carcinoma Syndrome, Non Hodgkin Lymphoma, Noonan Syndrome and Other Rasopathy, Overgrowth Syndromes, Pancreatic Cancer, Peutz-Jeghers Syndrome, Pheochromocytoma/Paraganglioma, PTEN Hamartoma Tumor Syndrome, Retinoblastoma, Rhabdoid Tumor Predisposition Syndrome, Rhabdomyosarcoma, Rothmund-Thomson Syndrome, Tuberous Sclerosis, Von Hippel-Lindau Disease
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2037
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions: Not listed
Lead sponsor: Johns Hopkins University; Other
Eligibility: 15 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Ovarian Cancer
Interventions: E39 peptide vaccine, E39 vaccine then J65 vaccine, J65 vaccine then E39 vaccine; Biological
Lead sponsor: COL George Peoples, MD, FACS; Federal
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adnexal Mass, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Hereditary Breast and Ovarian Cancer
Interventions: OVA360; Other
Lead sponsor: Aspira Women's Health; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 215 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Gynecologic Cancer, Ovary Cancer, Pancreatic Cancer, Breast Cancer, Lynch Syndrome, Hereditary Breast and Ovarian Cancer Syndrome, Colon Cancer, Endometrial Cancer, Uterus Cancer
Interventions: Free genetic testing and counseling group, IGNITE-TX Group, IGNITE-TX and free genetic testing and counseling group; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Neoplasm Female, Early Detection of Cancer, Hereditary Breast and Ovarian Cancer Syndrome, Magnetic Resonance Imaging
Interventions: Enhanced Usual Care, Decision Support; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 74 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Hereditary Breast/Ovarian Cancer (brca1, brca2), Lynch Syndrome, Genetic Variation, HBOC Syndrome, Hereditary Cancer Syndromes
Interventions: Patient Centered Clinical Decision Support (PC-CDS); Other
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 2,488 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Basal-Like Breast Carcinoma, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Breast Carcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Prostate Carcinoma, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Solid Neoplasm, Triple-Negative Breast Carcinoma
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Fallopian Tube Carcinoma, Hereditary Breast and Ovarian Cancer Syndrome, Ovarian Carcinoma, Primary Peritoneal Carcinoma
Interventions: Evaluation of Cancer Risk Factors, Medical Chart Review, Study of Socioeconomic and Demographic Variables; Procedure · Other
Lead sponsor: Gynecologic Oncology Group; Network
Eligibility: 30 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Culturally Targeted Narrative Video: "Is My Cancer Hereditary? Rosa Visits a Genetic Counselor.", FORCE Fact Sheet; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 332 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Richmond, Virginia

Conditions: Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)
Interventions: counseling intervention, educational intervention, survey administration, psychosocial assessment and care, supportive care; Other · Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 8 Years to 120 Years · Female only
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts

Conditions: BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome, Breast Ductal Carcinoma In Situ, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Lynch Syndrome, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Genetic Counseling, Genetic Testing, Survey Administration; Procedure · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 27,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Adult Solid Neoplasm, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Hereditary Breast and Ovarian Cancer Syndrome
Interventions: Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 7
States / cities: Duarte, California • Los Angeles, California • Sacramento, California + 3 more

Conditions: BRCA1-Related Hereditary Breast and Ovarian Cancer Syndrome, BRCA2-Related Hereditary Breast and Ovarian Cancer Syndrome, Hereditary Neoplastic Syndrome, Lynch Syndrome
Interventions: Discussion, Internet-Based Intervention, Survey Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Deleterious BARD1 Gene Mutation, Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Deleterious BRIP1 Gene Mutation, Deleterious EPCAM Gene Mutation, Deleterious MLH1 Gene Mutation, Deleterious MSH2 Gene Mutation, Deleterious MSH6 Gene Mutation, Deleterious PALB2 Gene Mutation, Deleterious PMS2 Gene Mutation, Deleterious RAD51C Gene Mutation, Deleterious RAD51D Gene Mutation, Hereditary Breast and Ovarian Cancer Syndrome, Premenopausal
Interventions: Laboratory Biomarker Analysis, Oophorectomy, Quality-of-Life Assessment, Salpingectomy, Salpingo-Oophorectomy; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 30 Years to 50 Years · Female only
Enrollment: 374 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2041
U.S. locations: 9
States / cities: Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 5 more

Conditions: Breast Cancer, Ovarian Cancer
Interventions: AZ2281 + Carboplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions: LY2606368; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: Genetic Counseling and Testing YouTube Video; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia

Conditions: Hereditary Cancer Syndrome
Interventions: Modified genetic counseling, Traditional genetic counseling; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 49 Years
Enrollment: 967 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Denver, Colorado • Portland, Oregon

Conditions: Breast Cancer, Ovarian Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: KRAS-variant and microRNA binding site mutation testing; Genetic
Lead sponsor: MiraKind; Other
Eligibility: 18 Years and older
Enrollment: 15,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2035
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions: Not listed
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2026
U.S. locations: 11
States / cities: Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more

Search by objective public record fields.

Pediatric Reporting of Adult-Onset Genomic Results

Familial Investigations of Childhood Cancer Predisposition

Genetic Risk: Whether, When, and How to Tell Adolescents

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients

Multifactorial Risk Assessment for Breast & Ovarian Cancer Risk Detection

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention

The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI

Patient Centered Clinical Decision Support for Hereditary Cancer Syndromes

Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199

CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing

Standard Genetic Counseling With or Without a Decision Guide in Improving Communication Between Mothers Undergoing BRCA1/2 Testing and Their Minor-Age Children

Identifying and Caring for Individuals With Inherited Cancer Syndrome

Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer

A Web-Based Program (Kindred) to Improve the Understanding of Genetic Cancer Risk and Cancer Genetic Testing in African American Families

Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations

AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer

Cancer Health Assessments Reaching Many

Attitudes About Childbearing And Fertility With Inherited Breast And Ovarian Cancer Syndromes (HBOC)

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry